Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11729032 | 0.94 | PPARA (0.56) | PPARGPPARA | |
| SCHEMBL11641221 | 0.89 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL11728381 | 0.89 | PPARA (0.64) | PPARGPPARA | |
| SCHEMBL8892864 | 0.88 | PPARA (0.51) | PPARGPPARA | |
| SCHEMBL11727489 | 0.85 | PPARG (0.45) | PPARGPPARA | |
| SCHEMBL5925159 | 0.84 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL5711742 | 0.83 | LDHA (0.64) | PPARGPPARA | |
| SCHEMBL11279349 | 0.83 | PPARG (0.49) | PPARGPPARA | |
| SCHEMBL11727460 | 0.81 | ALDH1A1 (0.52) | — | |
| SCHEMBL11883894 | 0.81 | PPARG (0.47) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120138088-A | Technological application method for improving yield of butene-based spinosad | 上海酵诚生物技术有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-117624398-A | Method for improving yield of polysaccharide of allium macrostemon Shang Zong and application | 四川轻化工大学 | 2024-03-01 | — | — | CN | claimed |
| CN-116536221-A | Bacillus subtilis BC-9 and application thereof in degrading hemicellulose | 内蒙古工业大学 | 2023-08-04 | — | — | CN | claimed |
| CN-114812622-B | High-sensitivity circuit based on third-order exception point | 电子科技大学 | 2023-05-02 | — | — | CN | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-4308716-B1 | HYBRID MOLECULE COMPRISING A FIBRIN-DERIVED CITRULLINATED PEPTIDE AND AN ANTIBODY OR ANTIBODY FRAGMENT WHICH BINDS TO CD38 AND/OR CD138, AND USES THEREOF | UNIV TOULOUSE 3 PAUL SABATIER (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4710766-A1 | MIXTURES OF AMBRUTICIN WITH AT LEAST ONE FURTHER PESTICIDE | BASF SE (DE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025223904-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-0005698-A1 | Di(halogenated phenoxyalkanoyl)peroxides and their use as herbicides | Kalo Laboratories, Inc. (US) | 1979-12-12 | — | — | EP | disclosed |
| US-4093664-A | PLANT GROWTH REGULATORS | KALO LABORATORIES, INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4008324-A | Phenoxyalkylcarboxylic acid salt of 1-cinnamyl-4-diphenylmethyl piperazine, method of preparation and antihypercholesteremic | LUDWIG MERCKLE KG (DT) | 1977-02-15 | — | — | US | disclosed |
| US-3984413-A | ANTILIPEMIC, ANTICHOLESTEROLEMIC; PERIPHERAL AND VASOLIDATIVE EFFECT | L. MERCKLE KG (DT) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | PPARG 2617/4885PPARA 3447/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | PPARG 1856/4885PPARA 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.